Pain and mobility outcomes following patient controlled lumbar plexus block for primary joint arthroplasty - Patient controlled lumbar plexus block

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2007-000982-38-GB

Enrollment

400

Registered

2007-04-17

Start date

2007-06-14

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain control after primary joint arthroplasty

Interventions

Trade Name: Chirocaine Product Name: Levobupivacaine Pharmaceutical Form: Solution for infusion INN or Proposed INN: LEVOBUPIVACAINE CAS Number: 27262471 Concentration unit: % (V/V) percent volume/vol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: i) ASA class I-II ii) Age > 18yr =65 years) F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: i) History of dementia ii) ASA class III-V iii) History of allergy to any of the medications used in the study. iv) Inflammatory polyarthritis of a severity likely to compromise postoperative mobility

Design outcomes

Primary

Measure	Time frame
Main Objective: The reduction in visual analogue scores (VAS) for pain at rest and with hip flexion and external rotation after administration of either a lumbar plexus block or intravenous morphine in patients undergoing primary hip or knee arthroplasty.;Secondary Objective: i) the level of assistance required for transfer from the supine to the sitting position and from the sitting position to the standing position and for mobilisation with a walking aid, ii) a timed 10 metre walk to assess walking velocity, and iii) a timed stair-climbing test. Data collection will commence on an hourly basis immediately after surgery and will continue until each patient has achieved the timed stair-climbing test. iv) Incidence of all complications associated with the analgesic techniques in both groups v) Incidence of nausea within the first 48 hours of hospital admission in both groups. vi) Amount of blood loss in both groups over a 48 hr period. ;Primary end point(s): Data collection will commence on an hourly basis immediately after surgery and will continue until each patient has achieved the timed stair-climbing test. This will conclude the trial for the participant.	—

Measure

Time frame

Main Objective: The reduction in visual analogue scores (VAS) for pain at rest and with hip flexion and external rotation after administration of either a lumbar plexus block or intravenous morphine in patients undergoing primary hip or knee arthroplasty.;Secondary Objective: i) the level of assistance required for transfer from the supine to the sitting position and from the sitting position to the standing position and for mobilisation with a walking aid, ii) a timed 10 metre walk to assess walking velocity, and iii) a timed stair-climbing test. Data collection will commence on an hourly basis immediately after surgery and will continue until each patient has achieved the timed stair-climbing test. iv) Incidence of all complications associated with the analgesic techniques in both groups v) Incidence of nausea within the first 48 hours of hospital admission in both groups. vi) Amount of blood loss in both groups over a 48 hr period. ;Primary end point(s): Data collection will commence on an hourly basis immediately after surgery and will continue until each patient has achieved the timed stair-climbing test. This will conclude the trial for the participant.

—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026